BioReference Laboratories, Elmwood Park, NJ, along with its specialty oncology division, GenPath, announced the launch of OnkoSight Advanced, a next-generation sequencing (NGS) assay that enables distinctive deoxyribonucleic acid (DNA) mutational profiling of tumor samples.
OnkoSight Advanced NGS testing provides targeted gene content that is aligned with the latest National Comprehensive Cancer Network (NCCN) and World Health Organization guideline recommendations, to provide critical insights into many of the most common cancer types. Additionally, OnkoSight Advanced panels each include key biomarkers: Tumor Mutation Burden (TMB) and Tumor-Only Microsatellite (MSI), which are critical when profiling advanced stage tumor malignancies to guide potential immunotherapy.
“OnkoSight Advanced NGS panels are tumor-type specific and optimized to exclude extraneous gene content, significantly improving clinical actionability and relevance of the data to effectively guide real-world oncology patient management,” says Bevan Tandon, MD, hematopathologist and molecular pathologist, director of Cancer Genomics at BioReference Laboratories. “Coupled with BioReference and GenPath’s comprehensive oncology test menu, OnkoSight Advanced empowers physicians to make informed decisions effectively and efficiently.”
“A cancer diagnosis and treatment path are difficult to address with patients and their families, which drives the importance of understanding a patient’s risk group and accurately diagnosing the type of cancer, to result in a targeted treatment strategy and prognosis assessment,” says Jon R. Cohen, MD, executive chairman of BioReference Laboratories. “The latest advancement from BioReference’s oncology division underscores the commitment to patient-centric care through our industry-leading result turnaround time with enhanced accuracy.”
For more information, visit GenPath.
